Literature DB >> 3779644

Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug.

K E Wallner, M W DeGregorio, G C Li.   

Abstract

The cytotoxic and pharmacological properties of hyperthermia and cis-diamminedichloroplatinum(II) (DDP) were studied in DDP-sensitive and DDP-resistant Chinese hamster ovary cells in vitro. Cytotoxicity was measured by cell survival using colony formation assay and cellular platinum levels were determined by atomic absorption spectrophotometry. Hyperthermia potentiated DDP cytotoxicity in both DDP-sensitive and DDP-resistant Chinese hamster ovary cells. Dose enhancement ratios increased from 1.4 to 6.5 over the temperature range of 39-43 degrees C. Cellular accumulation of platinum at 37 degrees C in the sensitive cells was 2.3- to 3.3-fold greater than that in the drug-resistant cells. Cellular accumulation of DDP was increased by factors of 1.5 and 2.2 at elevated temperature. DDP resistance did not confer cross-resistance to heat alone. The results suggest that hyperthermia could be used to circumvent DDP resistance.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3779644

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Local hyperthermia and systemic chemotherapy for treatment of recurrent melanoma.

Authors:  F Di Filippo; S Carlini; R Garinei; P Perri; M Anzà; F Ferranti; E Saracca; M Schiratti; F Cavaliere; R Cavaliere
Journal:  World J Surg       Date:  1995 May-Jun       Impact factor: 3.352

2.  Sensitization of C6 glioma to carboplatin cytotoxicity by hyperthermia and thymidine.

Authors:  J D Cohen; H I Robins; M J Javid
Journal:  J Neurooncol       Date:  1990-08       Impact factor: 4.130

Review 3.  Resistance to cisplatin and analogues: mechanisms and potential clinical implications.

Authors:  A de Graeff; R J Slebos; S Rodenhuis
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.

Authors:  S C Mann; P A Andrews; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Improvement of local control by regional hyperthermia combined with systemic chemotherapy (ifosfamide plus etoposide) in advanced sarcomas: updated report on 65 patients.

Authors:  R D Issels; J Mittermüller; A Gerl; W Simon; A Ortmaier; C Denzlinger; H Sauer; W Wilmanns
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

6.  Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination.

Authors:  Y Yonemura; T Fujimura; S Fushida; S Takegawa; T Kamata; K Katayama; T Kosaka; A Yamaguchi; K Miwa; I Miyazaki
Journal:  World J Surg       Date:  1991 Jul-Aug       Impact factor: 3.352

7.  Hyperthermic potentiation of BCNU toxicity in BCNU-resistant human glioma cells.

Authors:  V F Da Silva; M Feeley; G P Raaphorst
Journal:  J Neurooncol       Date:  1991-08       Impact factor: 4.130

8.  Enhancement of cisplatin (DDP) antitumor activity by 3-aminobenzamide in rat ovarian tumors sensitive and resistant to DDP in vivo.

Authors:  G Chen; W J Zeller
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

9.  Heat enhances the cytotoxicity of cis-diamminedichloroplatinum(II) and its analogues cis-1,1-cyclobutane-dicarboxylato(2R)-2-methyl-1,4- butanediammineplatinum(II) and cis-diammine(glycolato)platinum in vitro.

Authors:  I Takahashi; Y Maehara; H Kusumoto; S Kohnoe; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Magnetic nanoparticle hyperthermia enhancement of cisplatin chemotherapy cancer treatment.

Authors:  Alicia A Petryk; Andrew J Giustini; Rachel E Gottesman; Peter A Kaufman; P Jack Hoopes
Journal:  Int J Hyperthermia       Date:  2013-10-21       Impact factor: 3.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.